✦ LIBER ✦

The postabsorptive urinary hydroxyproline (Spot-HYPRO) in patients with multiple myeloma

✍ Scribed by Harvey B. Niell; Charles L. Neely; Genaro M. Palmieri

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 475 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810801)48:3<783::aid-cncr2820480321>3.0.co;2-h

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urinary excretion of retinol in patients

Urinary excretion of retinol in patients with multiple myeloma: A preliminary study

✍ Vladimir Gavrilov; Tikva Yermiahu; Rafael Gorodischer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 1 views

The prognostic value of soluble interleu

The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma

✍ Roberto Stasi; Maurizio Brunetti; Albertina Parma; Claudio Di Giulio; Edmondo Te 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

## Background: The effect of interleukin-6 (il-6), the major growth factor for myeloma cells, may be enhanced by soluble il-6 receptor (sil-6r). therefore, the current study investigated the clinical significance of serum sil-6r in patients with multiple myeloma (mm). ## Methods: Serum levels of

The impact of race on outcomes of autolo

The impact of race on outcomes of autologous transplantation in patients with multiple myeloma

✍ Pramvir S. Verma; Robin S. Howard; Brendan M. Weiss 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Induction of integrin β1 expression in b

Induction of integrin β1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma

✍ Morito Kurata; Yasunori Nakagawa; Kouhei Yamamoto; Kenshi Suzuki; Masanobu Kitag 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 1 views

The addition of interferon or high dose

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486

✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera

Prognostic significance of the S-phase f

Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

✍ Trendle, M.C.; Leong, T.; Kyle, R.A.; Katzmann, J.A.; Oken, M.M.; Kay, N.E.; Van 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the pr